These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31015346)

  • 1. OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.
    Evans K; Duan J; Pritchard T; Jones CD; McDermott L; Gu Z; Toscan CE; El-Zein N; Mayoh C; Erickson SW; Guo Y; Meng F; Jung D; Rathi KS; Roberts KG; Mullighan CG; Shia CS; Pearce T; Teicher BA; Smith MA; Lock RB
    Clin Cancer Res; 2019 Jul; 25(14):4493-4503. PubMed ID: 31015346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL.
    Wang Y; Liu Y; Zhou C; Wang C; Zhang N; Cao D; Li Q; Wang Z
    Leuk Lymphoma; 2020 Jul; 61(7):1660-1668. PubMed ID: 32091283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
    Moradi Manesh D; El-Hoss J; Evans K; Richmond J; Toscan CE; Bracken LS; Hedrick A; Sutton R; Marshall GM; Wilson WR; Kurmasheva RT; Billups C; Houghton PJ; Smith MA; Carol H; Lock RB
    Blood; 2015 Sep; 126(10):1193-202. PubMed ID: 26116659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
    Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
    Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
    Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
    Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
    Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Verma K; Zang T; Penning TM; Trippier PC
    J Med Chem; 2019 Apr; 62(7):3590-3616. PubMed ID: 30836001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model.
    Maddeboina K; Jonnalagadda SK; Morsy A; Duan L; Chhonker YS; Murry DJ; Penning TM; Trippier PC
    J Med Chem; 2023 Jul; 66(14):9894-9915. PubMed ID: 37428858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
    Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
    Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma.
    Xun C; Zhang Y; Zheng X; Qin S
    J Pharmacol Sci; 2023 Jun; 152(2):69-75. PubMed ID: 37169481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.
    Meng F; Li WF; Jung D; Wang CC; Qi T; Shia CS; Hsu RY; Hsieh YC; Duan J
    Am J Cancer Res; 2021; 11(7):3645-3659. PubMed ID: 34354865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker.
    Reddi D; Seaton BW; Woolston D; Aicher L; Monroe LD; Mao ZJ; Harrell JC; Radich JP; Advani A; Papadantonakis N; Yeung CCS
    Sci Rep; 2022 Apr; 12(1):5809. PubMed ID: 35388063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
    Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
    Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo.
    Chen J; Yang Y; Xu D; Li J; Wu S; Jiang Y; Wang C; Yang Z; Zhao L
    Biochem Biophys Res Commun; 2021 Feb; 540():83-89. PubMed ID: 33450484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
    Caracciolo D; Riillo C; Ballerini A; Gaipa G; Lhermitte L; Rossi M; Botta C; Duroyon E; Grillone K; Gallo Cantafio ME; Buracchi C; Alampi G; Gulino A; Belmonte B; Conforti F; Golino G; Juli G; Altomare E; Polerà N; Scionti F; Arbitrio M; Iannone M; Martino M; Correale P; Talarico G; Ghelli Luserna di Rorà A; Ferrari A; Concolino D; Sestito S; Pensabene L; Giordano A; Hildinger M; Di Martino MT; Martinelli G; Tripodo C; Asnafi V; Biondi A; Tagliaferri P; Tassone P
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of AST-001 non-clinical pharmacokinetics: A novel selective AKR1C3-activated prodrug in mice, rats, and cynomolgus monkeys.
    Meng T; Jung D; Cai XH; Lu ZQ; Yu JB; Qi TY; Meng FY; Ruan MZ; Duan JX
    Biopharm Drug Dispos; 2024 Apr; 45(2):83-92. PubMed ID: 38492211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor.
    Morsy A; Trippier PC
    ACS Chem Biol; 2020 Mar; 15(3):646-650. PubMed ID: 32125151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
    Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.
    Jones L; McCalmont H; Evans K; Mayoh C; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27765. PubMed ID: 31012549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
    Wang B; Gu Y; Hui K; Huang J; Xu S; Wu S; Li L; Fan J; Wang X; Hsieh JT; He D; Wu K
    Urol Oncol; 2018 Oct; 36(10):472.e11-472.e20. PubMed ID: 30139661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.